Lawmakers press Sharpless to bring stem cell companies into line

A bipartisan group of four legislators are pushing acting FDA Commissioner Ned Sharpless to regulate unproven stem cell therapies as they claim the number of companies marketing stem cell treatments in compliance with premarket approval requirements

Read the full 367 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE